The Cancer Genome Atlas proposed that NF1 mutations should be included for classification in BRAFwt/NRASwt melanoma, since reports were available showing that mutations in NF1 led to hyper-activation of the MAPK pathway and were responsive to MEK inhibition [16,37,38]. The gene discussed is NF1; the disease is melanoma.